A predictive artificial intelligence (AI) biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer was validated in a recent study published in NEJM Evidence. Results of a phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback